Drug Profile
LGD 1268
Alternative Names: ALRT 268; LG 100268Latest Information Update: 16 Feb 2006
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Ligand Pharmaceuticals
- Class Antihyperglycaemics; Antineoplastics; Nicotinic acids; Small molecules
- Mechanism of Action Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 16 Feb 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 07 Feb 2001 Discontinued-Preclinical for Hyperlipidaemia in USA (Unknown route)
- 23 Mar 1999 Discontinued-Preclinical for Type-2 diabetes mellitus in USA (Unknown route)